Balt USA has announced that it has obtained CE mark for the Titan aspiration catheter. The Titan catheter line consists of a highly navigable, large bore (0.070”) aspiration catheter and a smaller bore (0.036”) catheter for navigation and support.
Obtaining the CE mark for Titan* enhances the Balt stroke portfolio as it will be available alongside the CatchView* revascularisation stent, Vasco* catheters, Ballast long sheath and Hybrid guidewires to provide a complete stroke solution to the marketplace.
“Titan marks the sixth significant product approval obtained by Balt within the last year and contributes to Balt’s rapid succession of products to the neurovascular community,” said Pascal Girin, CEO at Balt.
Balt USA was established in 2017 as the USA-based division of Balt Incorporated and is based in Irvine, California. Currently, Balt USA’s focus is on the commercialisation of Balt products in the USA as well as continuing a tradition of physician inspired innovation through research and development.
*The Titan aspiration catheter, CatchView revascularization stent and Vasco catheters arenot cleared or approved for sale in the United States
